Zytiga nabs EMA approval for broad use; OTC drugmakers see sales spike on flu season;

@FiercePharma: Zytiga wins European approval for earlier use. FDA did the same in December. Could be big for Janssen/J&J. More | Follow @FiercePharma

 @AlisonBFierce: Widespread flu outbreak gives vaccine manufacturers a shot in the arm. News | Follow @AlisonBFierce

> European regulators approved a big expansion in the use of Johnson & Johnson's ($JNJ) prostate cancer pill Zytiga, following the FDA's similar approval last month. Report

> Makers of over-the-counter flu and cold remedies are benefiting from this year's unusually strong flu season. Report

> Novartis ($NVS) says a new late-stage trial found that its meningitis vaccine Bexsero delivered a protective immune response in infants with a three-dose regimen, with additional effect after a booster in toddlers. Report

> GlaxoSmithKline ($GSK) has drawn the ire of small suppliers with new 90-day payment terms, which the company says are consistent with its corporate peers. Report

> As Roche ($RHHBY) prepares to pull out of Nutley, NJ, it's receiving offers for the 119-acre property and working to find jobs for laid-off workers. Report

> Lundbeck recruited Bayer Healthcare's Barbara Jaszewski to be its senior VP of global product strategy and portfolio development. Report

> Astellas Pharma won European approval for its overactive bladder treatment, Betmiga. Report

Biotech News

 @FierceBiotech: Trending on FierceBiotech.com: $GSK pilots 6th drug to regulators in R&D offensive. More | Follow @FierceBiotech

@JohnCFierce: Activists cry havoc, let slip the dogs of war on AstraZeneca. News | Follow @JohnCFierce

@RyanMFierce: PatientsLikeMe tackles extremely rare genetic disease. Item | Follow @RyanMFierce

> Eisai's pivotal hopes for ovarian cancer drug dashed by PhIII flop. Story

> Aileron snags $12M to fuel first human study of 'stapled' peptide. Article

Medical Device News

 @FierceMedDev: Experts: Odds of device tax repeal close to zero. Item | Follow @FierceMedDev

@MarkHFierce: Covidien begins postapproval study for stroke treatment device. More | Follow @MarkHFierce

 @DamianFierce: Last thing from JPM13: Talking Chinese outsourcing with Vertex, Merck, MedImmune and WuXi. Story | Follow @DamianFierce

> J&J's other hip device lands it back in court. Story

Biotech IT News

> How 'open' will Big Pharma get to treat R&D ills? Item

> Computer game rewards players for shirking flu shots. Report

> Elsevier snaps up drug R&D software company. Article

> Illumina, Life Tech trumpet startup efforts in clinical genomics. News

CRO News

> Report: Indian drug-related trial deaths rose in 2012. Report

> goBalto inks deal with INC for trial software. Article

> Catalent breathes $20M into inhalant business. News

> GVK partners with Onconova on cancer drugs. Story

> Parexel chief named ACRO chairman. Item

And Finally... Stroke survivors with depression are four times more likely to die than those who aren't depressed. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.